Selling, General, and Administrative Costs: Eli Lilly and Company vs Walgreens Boots Alliance, Inc.

A Comparative Analysis of SG&A Expenses: Eli Lilly vs. Walgreens Boots Alliance

In the ever-evolving landscape of corporate finance, understanding the nuances of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Eli Lilly and Company and Walgreens Boots Alliance, Inc. have showcased distinct financial trajectories in this domain. From 2014 to 2023, Eli Lilly's SG&A expenses have seen a modest increase of approximately 5%, peaking at $6.94 billion in 2023. In contrast, Walgreens Boots Alliance has experienced a more pronounced growth of around 44%, reaching $25.48 billion in the same year. This disparity highlights the differing strategic priorities and operational scales of these two industry giants. Notably, the data for 2024 is incomplete for Eli Lilly, indicating potential shifts or reporting delays. As these companies continue to navigate the complexities of the healthcare and retail sectors, their SG&A trends offer valuable insights into their operational efficiencies and market strategies.